The SAVE-MORE RCT evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure (identified by plasma soluble urokinase plasminogen activator receptor serum levels). Here, IL1A is linked to respiratory failure.